BeOne Medicines Ltd. (ONC)
ONC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ONC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Cayman Islands |
| IPO year | 2016 |
| SEC CIK | 0001651308 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.3B |
| Net income | $286.9M |
| Operating income | $447.1M |
| Net margin | 5.4% |
| Operating margin | 8.4% |
| Revenue growth | +40.2% |
| Cash | $4.5B |
| Total assets | $8.2B |
| P/E (computed) | 163.7× |
| P/S (computed) | 8.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $5.8B cash; operating cash flow $397.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 114,226,079 (2026-10-30); 110,657,943 a year earlier; 104,576,740 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $372.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.9B | $384.7M | $508.7M | $5.8B | $866.2M | $6.6B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.7B | $237.0M | $462.8M | $5.1B | $859.9M | $6.1B | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $1.5B | $227.4M | $201.3M | $4.8B | $852.2M | $5.7B | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $1.5B | $66.5M | $417.3M | $4.5B | $845.4M | $5.3B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $1.4B | $124.8M | $402.6M | $4.0B | $1.6B | $5.0B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $1.3B | $94.3M | $263.6M | $2.8B | $954.5M | $4.6B | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $1.1B | $1.3M | $44.1M | $2.5B | $923.6M | $4.2B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $1.1B | -$151.9M | $75.2M | $2.6B | $1.9B | $3.8B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-05-06 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | +19.3% |
| 3 months | +17.0% |
| Year to date | +37.1% |
| 1 year | +13.1% |
| From 52-week high | -1.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | $42.57 | -4.34% | $49.7B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier